Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 2Terminated 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Neuroblastoma 4Melanoma 4Prostatic Neoplasms 3Neoplasm Metastasis 3Myelodysplastic Syndromes 3Multiple Myeloma 3Lymphoma 3Leukemia, Myeloid, Acute 3Ganglioneuroblastoma 3Uveal Melanoma 2Osteosarcoma 2Lymphoma, Non-Hodgkin 2Lung Neoplasms 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Sarcoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Neoplasms, Plasma Cell 1Lymphoma, T-Cell 1Lymphoma, Follicular 1Leukemia, Myelomonocytic, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Lymphoid 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Erythroblastic, Acute 1Kidney Neoplasms 1

Interventions

Prednisone 112Docetaxel 87Leuprolide 79enzalutamide 72Abiraterone Acetate 67bicalutamide 53Goserelin 50acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 42Radiotherapy 39abiraterone 28Magnetic Resonance Spectroscopy 27Gonadotropin-Releasing Hormone 24gallium 68 PSMA-11 23apalutamide 22Androgen Antagonists 22luprolide acetate gel depot 21sipuleucel-T 20Radiosurgery 20Triptorelin Pamoate 18cabazitaxel 17cabozantinib 16Radiotherapy, Intensity-Modulated 16Flutamide 16pembrolizumab 15radium Ra 223 dichloride 14Prednisolone 14Nivolumab 14Dutasteride 14Dexamethasone 14Radiation 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × Prostatic Neoplasms × Colony-Stimulating Factors × Clear all
NCT00274287 2019-03-28

GM-CSF for Maintenance of Prostate Cancer for Patients Responding to Taxotere

Oncology Specialists, S.C.

Phase 2 Completed
15 enrolled 12 charts
Genitourinary

Prostatic Neoplasms

NCT00477087 2017-11-29

Phase II GM-CSF Plus Mitoxantrone in Hormone Refractory Prostate Cancer

Stanford University

Phase 2 Terminated
10 enrolled 10 charts
Genitourinary

Prostatic Neoplasms

NCT00108732 2015-06-30

A Phase II Study of PROSTVAC-V (Vaccinia)/TRICOM and PROSTVAC-F (Fowlpox)/TRICOM With GM-CSF in Patients With PSA Progression After Local Therapy for Prostate Cancer

National Cancer Institute (NCI)

Phase 2 Completed
50 enrolled 7 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡